Event: Pharma Business Development Course
Dates: August 22 - 23, 2012
Venue: Holiday Inn Jiuzhai Jarpo, Sichuan
Price: CNY 17,800
Phone: +86 186 0126 7831
Business Development in the pharmaceutical industry has become the most significant source of new products for most companies. Although forward integration from research to market still exists it is no longer the mainstay of corporate growth. Business Development is now conducted throughout every organization which requires personnel in all disciplines to understand their role in bringing new products into the company whether they are head office based or located in a subsidiary.
The importance of having a structured process through the company ensure that there is coordination of efforts and alignment of strategy to make best use of resources. Concentrating on key global products will enhance their chances of success yet at regional or affiliate company level there is also a need to address the particular needs of the local countries.
The Pharmaceutical Business Development Course has been written and developed over the last five years to capture and structure the processes needed to bring about a successful transaction which can then be distributed as a best practice in the organization.
Attendees on this 2 days intensive program will have the chance to learn and to gain an insight into areas such as:
1. Understanding and creating a balanced portfolio of products;
2. How to profile the most suitable products for the company;
3. Where and how to search out suitable opportunities;
4. Conduct a Valuation of the asset to form the basis of a Term sheet for negotiation;
5. Turing a term sheet into a negotiation strategy and conducting the interactions between in
the best managed way;
6. Executing and managing the contract in good times and in bad; and
7. Converting the negotiation into an executable contact while avoiding major pitfalls of legal
Martin Austin, he was between 2000 and 2005 a Principal in the Paul Capital Partners Royalty Funds, a USA based specialist in Secondary Private Equity and Alternative Asset Investments with some US$6 Billion under management. Before this between 1995 and 2000 he was Head of Business Development for the Pharmaceuticals Division at F. Hoffmann-La Roche.
Prior to joining Roche he was Managing Director of MHIG Ltd a London based Anglo-German Market Research company specialising in long term studies of prescribing in Oncology and using hand held computers to monitor prescribing and outcomes analysis in hospitals.
He started his Pharmaceutical career with GD Searle the US pharmaceutical firm as a Sales Representative progressing through Product Management and Marketing Management positions to become Business Development manager at Lorex Pharmaceuticals a joint venture between Searle and Synthélabo of France where he established the company to launch Tildiem and Kerlone into the UK market.He has recently published "Business Development for the Biotechnology and Pharmaceutical Industry" based on the courses he presents with CELforpharma (Brussels), Pharmaguys (Beijing), the World Intellectual Property Organisation of the United Nations and at Basel University as a part of the Masters in Drug Development Sciences degree course.